Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

(2013) D. K. Hiwase et al.   HAEMATOLOGICA

A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction

(2013) Y. Shinohara et al.   HAEMATOLOGICA

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib

(2011) T. P. Stromskaya et al.   BIOCHEMISTRY-MOSCOW

OCT-1 as a Determinant of Response to Antileukemic Treatment

(2011) J R Engler et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1

(2011) Marta Gromicho et al.   LEUKEMIA & LYMPHOMA

Mechanisms of resistance to BCR–ABL kinase inhibitors

(2011) Joana M. Diamond et al.   LEUKEMIA & LYMPHOMA

Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes

(2011) Cliff Chen et al.   XENOBIOTICA

Long-term outcomes in the second-line treatment of chronic myeloid leukemia

(2010) Elias Jabbour et al.   CANCER

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

(2010) K. Eechoute et al.   CLINICAL CANCER RESEARCH

Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia

(2010) N Takahashi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

The impact of gene profiling in chronic myeloid leukaemia

(2009) Agnes S.M. Yong et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance

(2009) Wenyong W. Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial treatment for patients with CML

(2009) J. M. Goldman   Hematology-American Society of Hematology Education Program

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

(2008) John M. Goldman et al.   ACTA HAEMATOLOGICA

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

(2008) T. P. Hughes et al.   BLOOD

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations

(2008) Tomoka Furukawa et al.   PHARMACEUTICAL RESEARCH

Organic cation transporters

(2008) G. Ciarimboli   XENOBIOTICA